PLX130524

GSE133822: T cell and Monocyte Specific RNAseq Analysis in Septic and Non Septic Critically-Ill Patients and in Patients with Cancer

• Organsim human
• Type RNASEQ
• Target gene
• Project ARCHS4

The purpose of this study was to determine the potential differential effect of sepsis on innate versus adaptive immune effector cells by examining RNA expression in monocyte/macrophages and CD4 and CD8 T cells respectively using next generation sequencing.; [SUBMITTER_CITATION]:; In Press Journal of Immunology; T cell and Monocyte Specific RNAseq Analysis in Septic and Non Septic Critically-Ill Patients and in Patients with Cancer Michael L. Washburn*, Zhang Wang*?, Andrew H. Walton?, S. Peter Goedegebuure, David J. Figueroa*, Stephanie Van Horn*, Julie Grossman, Katja Remlinger*, Heather Madsen*, James Brown*, Roopa Srinivasan*, Amaya I. Wolf*, Scott B. Berger*, Victoria Yi?, William G. Hawkins, Ryan C. Fields, Richard S. Hotchkiss?||; * GlaxoSmithKline, Pharmaceuticals Research and Development, Upper Providence, PA USA ? Institute of Ecological Science, School of Life Science, South China Normal University, Guangzhou, 510630, China ? Department of Anesthesiology, Washington University St. Louis, School of Medicine, St. Louis, MO 63110 USA Department of Surgery, Washington University St. Louis, School of Medicine, St. Louis, MO 63110 USA Siteman Cancer Center, Washington University St. Louis, School of Medicine, St. Louis, MO 63110 USA; || Department of Medicine, Washington University St. Louis, School of; || Medicine, St. Louis, MO 63110 USA; Address correspondence and reprint requests to Dr. R.S. Hotchkiss, Washington University School of Medicine, 660 S. Euclid, St Louis, MO 63110 or to Dr. Michael L. Washburn, Glaxo Smith Kline Pharmaceuticals R&D, 1250 South Collegeville Road, Collegeville, PA 19426. michael.l.washburn@gsk.com This work was supported by grants from the National Institutes of Health GM 126928 (to R.S.H.) and from the National Cancer Institute P50CA196510 and from research support by GlaxoSmithKline SOURCE: James,Raymond,Brown (James.R.Brown@gsk.com) - GlaxoSmithKline